{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:21:25Z","timestamp":1793733685393,"version":"4.6.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Severance Hospital Research fund for Clinical excellence","award":["C-2025-0029"],"award-info":[{"award-number":["C-2025-0029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Somatic hypermutation (SHM) of the immunoglobulin heavy chain variable (\n                      <jats:italic>IGHV<\/jats:italic>\n                      ) region is a key prognostic marker in chronic lymphocytic leukemia (CLL). Traditionally, SHM status has been determined using Sanger sequencing (SS); however, next-generation sequencing (NGS) provides an alternative method for assessing both SHM status and clonal rearrangements. This study aimed to compare the performance of two commercially available NGS assays for evaluating\n                      <jats:italic>IGH<\/jats:italic>\n                      clonality and SHM status in CLL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 42 samples from patients diagnosed with CLL were analyzed. Genomic DNA extracted from peripheral blood or bone marrow aspirates was analyzed using two commercial NGS assays: the LymphoTrack\u00ae\n                      <jats:italic>IGHV<\/jats:italic>\n                      Leader (Leader) and\n                      <jats:italic>IGH<\/jats:italic>\n                      FR1 (FR1) assays (Invivoscribe, CA, USA). SS was performed as the reference method for SHM assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Leader assay identified clonality in 95.2% of cases, whereas the FR1 assay detected clonality in 88.1%. Conclusive SHM status was determined in 90.5% of samples using the Leader assay and in 76.2% using the FR1 assay; when results from both assays were combined, the rate increased to 92.9%. Among samples with conclusive results by both SS and each NGS assay, the Leader assay demonstrated higher concordance with SS (97.1%, 34\/35) than the FR1 assay (86.2%, 25\/29). Greater variability in clonal detection was observed with the FR1 assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that the Leader assay provides a more reliable assessment of SHM status, with higher concordance with SS. Although the FR1 assay may offer additional information regarding clonal patterns, its results should be interpreted cautiously. Given the limited sample size, further studies are warranted to validate these findings. Overall, the Leader assay appears to be more suitable as a primary tool for SHM evaluation, with FR1 results serving a complementary role when interpreted in clinical context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-026-00132-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T03:49:33Z","timestamp":1775447373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative evaluation of two NGS-based assays for somatic hypermutation analysis of IGHV genes in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"61","author":[{"given":"Yehyun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Rak","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeam","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"132_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/302575a0","volume":"302","author":"S Tonegawa","year":"1983","unstructured":"Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302:575\u201381.","journal-title":"Nature"},{"key":"132_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/2040620713519729","volume":"5","author":"A Gazzola","year":"2014","unstructured":"Gazzola A, Mannu C, Rossi M, et al. The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. Ther Adv Hematol. 2014;5:35\u201347.","journal-title":"Ther Adv Hematol"},{"key":"132_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","volume":"37","author":"L Mansouri","year":"2023","unstructured":"Mansouri L, Thorvaldsdottir B, Sutton L-A, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023;37:339\u201347.","journal-title":"Leukemia"},{"key":"132_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","volume":"36","author":"A Agathangelidis","year":"2022","unstructured":"Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia. 2022;36:1961\u20138.","journal-title":"Leukemia"},{"key":"132_CR5","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood-2017-07-731588","volume":"130","author":"C Chai-Adisaksopha","year":"2017","unstructured":"Chai-Adisaksopha C, Brown JR. FCR achieves long-term durable remissions in patients with IGHV-mutated CLL. Blood. 2017;130:2278\u201382.","journal-title":"Blood"},{"key":"132_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1038\/s41375-020-0923-9","volume":"34","author":"F Davi","year":"2020","unstructured":"Davi F, Langerak AW, de Septenville AL, et al. Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. Leukemia. 2020;34:2545\u201351.","journal-title":"Leukemia"},{"key":"132_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","volume":"21","author":"ME Arcila","year":"2019","unstructured":"Arcila ME, Yu W, Syed M, et al. Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms. J Mol Diagn. 2019;21:330\u201342.","journal-title":"J Mol Diagn"},{"key":"132_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jmoldx.2023.01.009","volume":"25","author":"E Bourbon","year":"2023","unstructured":"Bourbon E, Chabane K, Mosnier I, et al. Next-CLL, a new next-generation sequencing\u2013based method for assessment of IGHV gene mutational status in chronic lymphoid leukemia. J Mol Diagn. 2023;25:274\u201383.","journal-title":"J Mol Diagn"},{"key":"132_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/jcmm.12215","volume":"18","author":"C Ren\u00e9","year":"2014","unstructured":"Ren\u00e9 C, Prat N, Thuizat A, Broctawik M, Avinens O, Eliaou JF. Comprehensive characterization of immunoglobulin gene rearrangements in patients with chronic lymphocytic leukaemia. J Cell Mol Med. 2014;18:979\u201390.","journal-title":"J Cell Mol Med"},{"key":"132_CR10","first-page":"1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood J Am Soc Hematol. 1999;94:1848\u201354.","journal-title":"Blood J Am Soc Hematol"},{"key":"132_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jmoldx.2023.02.005","volume":"25","author":"K Petrova-Drus","year":"2023","unstructured":"Petrova-Drus K, Syed M, Yu W, et al. Clonal characterization and somatic hypermutation assessment by next-generation sequencing in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a detailed description of the technical performance, clinical utility, and platform comparison. J Mol Diagn. 2023;25:352\u201366.","journal-title":"J Mol Diagn"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00132-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00132-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00132-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:16:10Z","timestamp":1775560570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00132-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["132"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00132-7","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was exempt from ethical review by the Institutional Review Board of Severance Hospital (IRB No. 4\u20132024-0638).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}